Urotensin I acetate (83930-33-0 Free base) is a CRF-like neuropeptide (natural product), a CRF receptor agonist (EC50 as low as 3.5 pM for hCRF1, Ki=0.4 nM), with high affinity and receptor subtype selectivity, used for CRF receptor functional research.

α-helical CRF 9-41 acetate is a competitive antagonist of CRF2 (KB = 100 nM) and a partial agonist of CRF1 (EC50 = 140 nM).

Urocortin (rat) acetate is a potent, selective CRFR agonist with Ki values of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α, and mouse CRF2β, respectively. Urocortin (rat) acetate exhibits cardioprotective, anti-inflammatory, and immunomodulatory activities. Urocortin (rat) acetate can be used in cardiovascular protection and immune-inflammatory research.

K41498 acetate, an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 acetate is a potent and highly selective antagonist CRF2 receptor with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β and CRF1 receptors respectively.

Urocortin, human (Human urocortin I) is a 40 amino acid peptide which is closely related to corticotrophin-releasing factor (CRF).

Antalarmin hydrochloride is an antagonist of corticotropin-releasing factor 1(CRF1). Antalarmin hydrochloride produces anti-inflammatory effects and suppresses stress-induced gastric ulceration related to irritable bowel syndrome.

Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .

(R)-Crinecerfont is an enantiomeric counterpart of SSR-125543. SSR-125543 is a potent CRF-R1 antagonist with Ki = 1.0 nM for human CRF-R1.

CP 376395 (CP-316311) is an effective and specific Corticotropin-releasing factor 1 (CRF1) receptor antagonist.

CP 316311 is a specific CRF1 receptor antagonist with potential antidepressant activity and may be used in the study of depression.

Astressin acetate is an antagonist of corticotropin releasing factor (CRF) with low affinity for the CRF binding protein and high affinity for the cloned pituitary receptor(Ki = 2 nM).

NBI-27914 is a selective and non-peptide CRFR1 (corticotropin-releasing factor receptor 1) antagonist with analgesic effects, capable of blocking CRF-induced anxiety.

R121919 (NBI30775) is a potent small molecule antagonist of the adrenocorticotropic hormone-releasing factor receptor 1 (CRF1), demonstrating antidepressant and anxiolytic activity, and inhibiting the CRF1 receptor, CRF2 receptor, and CRF-binding proteins.

Corticotropin-releasing factor (human) acetate stimulates to synthesize and secret adrenocorticotropin in the anterior pituitary.

CRF (6-33) acetate is a corticotropin-releasing factor binding protein (CRFBP) inhibitor peptide; displaces CRF from CRFBP. Suppresses body weight gain and increases motor activity in obese rats in vivo.

Crinecerfont (SSR-125543) is a selective antagonist of corticotropin-releasing factor 1 receptor (CRF1) and can be used in studies about Classic congenital adrenal hyperplasia.

Pexacerfont (BMS-562086) is a selective antagonist of the corticotropin-releasing factor receptor (IC50: 6.1±0.6 nM for the human CRF1 receptor).

Cosyntropin (acetate) stimulates the release of corticosteroids such as cortisol from the adrenal gland.

Tetracosactide (Tetracosactrin) (INN) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone.

Tildacerfont is an antagonist of CRF1 and reduces the levels of adrenocorticotropic hormone and adrenal androgen. Tildacerfont can be used in studies about congenital adrenal hyperplasia.

Antalarmin is a selective and potent corticotropin-releasing factor receptor 1 (CRHR1) antagonist that crosses the blood-brain barrier and blocks CRF activation and carrageenan-induced subcutaneous inflammation in rats.

CP 154526 hydrochloride is a blood-brain barrier-penetrant, selective CRF1 (corticotropin-releasing factor receptor 1) antagonist (Ki = 2.7 nM) exhibiting thousands of times greater selectivity for CRF1 over CRF2, with anxiolytic and antidepressant activities.

DMP 696 is a selective antagonist of corticotropin-releasing hormone receptor 1. It is used for the treatment of anxiety and depression.

Potent and selective corticotropin releasing factor receptor-1 (CRF1) agonist (Ki values are 1.5 and 224 nM for CRF1 and CRF2 receptors respectively). Increases ACTH levels and increases faecal pellet output in vivo following i.p. administration.